Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00864604 · ClinicalTrials.gov registry record · Phase 1

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT00864604 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00864604, a Phase 1 study of Healthy, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence

Conditions Studied

Interventions

  • DRUG Nabumetone 750 mg tablets, single dose

Study Locations (1)

North Carolina

  • AAIPharma Inc., AAI Clinic - Morrisville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2007-04
Est. Completion 2007-05
Phase Phase 1

Sponsor

Actavis

79 total trials

What the Registry Record Tells You About NCT00864604

The ClinicalTrials.gov registry entry for NCT00864604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Nabumetone 750 mg tablets, single dose is the first listed.

NCT00864604 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00864604 about?

NCT00864604 is a clinical study titled "Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers". The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence

What is the current status of trial NCT00864604?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-04. Estimated completion is 2007-05.

What conditions does trial NCT00864604 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00864604?

The interventions under investigation include: Nabumetone 750 mg tablets, single dose (DRUG).

Who is sponsoring clinical trial NCT00864604?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00864604 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.